Report Overview

United States IUD Market- Industry Trends & Forecast Report 2027

United States IUD market was worth USD 900 Million in 2020, further projected to grow at a CAGR of 4.9% during the forecast period (2021-2027) to reach the valuation of USD 1,210.1 Million by 2027. IUD market growth in the United States has been primarily driven by the increase in unintended pregnancies and government initiatives, such as providing free IUDs to women from low-income communities. In addition, the inclusion of birth control contraceptives in the Affordable Care Act (ACA) and the provision of medical coverage to women has been a significant element in the growth of the United States IUDs Market. Additionally, higher regulatory approvals and increased competition among pharmaceutical manufacturers for producing IUDs have are also favoring the market’s growth.

Source: BlueWeave Consulting

United States IUD Market Overview

IUDs are T-shaped plastic strips that are inserted into the uterus to prevent conception. Copper-coated IUD prevents fertilization of the egg by restricting sperm entrance. These devices are planted with the help of doctors or nurses. For instance, Oncit is a device implanted into the uterus that helps prevent undesired or forced pregnancy for an extended period of time (3 to 10 years). Women of lower-income class and those of middle-to-high income class who wish not to bear children are making long-term birth control measures like these more popular. It is estimated that IUDs have a 98% effectiveness rate according to IPPF (International Planned Parenthood Federation). Preventing pregnancy using the hormonal type is effective in 98% of cases. However, with time this tends to witness some loss of ineffectiveness.

United States IUD Market Trend

Growth Drivers

Higher Rates of Effectiveness Compared to Other Methods

There are two types of IUDs currently present in the IUDs market, namely, Hormonal IUDs & Non-Hormonal (Copper) IUDs. The effectiveness across the two types of IUDs differs in terms of emergency usage and the possibility of pregnancy under unprotected intercourse. Hormonal IUDs are not effective in case of emergency; however, they still dominate the United States IUD market due to their higher effectiveness. An estimated 2 to 8 in every 1,000 women (0.2 per 100 women for Mirena) who have IUDs get pregnant in a year of typical use. IUDs are so effective as there is no chance of mistakes, skipping, or taking contraceptive pills. Thus, the high rate of effectiveness of IUD as compared to other contraceptives has propelled the market growth.

Fig: Estimated Numbers Of Women (Million) Of Reproductive Age (15-49 Years) Using Various Contraceptive Methods, 1994 And 2019

Source: Secondary Search & BlueWeave Consulting 

Restraint

An IUD May Increase the Possibility of Pregnancy Complications

Women use IUDs to prevent the risk of pregnancies for a more extended period. However, studies have reported that the risk of preterm birth, miscarriage, and infection of the amniotic sac and chorioamnionitis (fluid before delivery) is significantly higher when IUDs are left in place during pregnancy compared to pregnancies in which the IUD is removed. Very few women (2% to 10%) experience misplacements of their IUDs either completely or partially. Moreover, getting pregnant with an IUD increases the risk of ectopic or tubal pregnancy, which can damage the reproductive organs. Additionally, preterm birth may lead to multiple side effects, such as cerebral palsy, impaired learning, vision problems, hearing problems, dental problems, and others. Because of the numerous side effects, most women opt not to use many of the IUDs available for women, thus impeding the growth of the United States IUD market.

Impact Of COVID-19

The pandemic caused by COVID-19 caused significant volatility and uncertainty in the United States and global economies, elevating operational risks in early 2020.  Women in the U.S are more likely than men to have lost work during the pandemic. Additionally, because of the huge increase in general unemployment, many people have lost their job-related health insurance, limiting their access to health care. Thus, women's access to contraception and other SRH services, as well as their ability to pay for these services, has been limited during the pandemic. Furthermore, due to the pandemic's interruptions, many patients are unable to receive their preferred method of contraception. Several women have been unable to get long-acting birth control, including intrauterine devices (IUDs) or implants, as they require in-person visits. Instead, they resorted to less effective measures that can be carried out via telemedicine, such as pills.

United States IUD Market: By Type

There are two types of IUDs in the United States IUDs market: hormonal and copper. Hormonal IUD segment accounted for the largest market share in 2020 and is expected to grow significantly. Since numerous side effects plague copper IUDs, the segment is expected to decline during the forecast period. Hormonal IUDs are trending across the United States region and likely hold significant market share in the upcoming years.

The FDA has approved five distinct IUDs in the United States, all of which are safe for adolescents and young adults. ParaGard, Mirena, Liletta, Kyleena, and Skyla are popular brands across the region. The different varieties of IUDs have similar effectiveness. Patients can remove all of them if they wish to try to conceive before the device expires or if they no longer wish to use the device due to adverse effects. A variety of factors must be discussed between the patient and healthcare provider before an IUD is chosen.

Competitive Landscape

The leading players in the United States IUD market are Bayer AG, Cooper Companies (CooperSurgical Inc), and AbbVie. Bayer is the market leader in the area of Hormonal IUD.

The prominent market players in the United States IUDs market compete based on price and product quality. Given that capital expenditure needed to set up a business is not prohibitive, small and medium market players are expected to demonstrate considerable improvement in the near future. Nevertheless, large companies will likely aim for global expansion to gain a more significant brand reputation.

Recent Developments

• In 2020, the New England Journal of Medicine published a research stating that Skyla is the newest arrival in the hormonal IUD market. It is a smaller & lower-dose version of the other hormonal IUD better known as Mirena IUD.  Mirena IUD was restricted to those women who had already conceived. However, there is no such restriction in the Skyla IUD.

• In 2020, Bayer partnered with Direct Relief and launched the "We're for Her" initiative. The primary purpose of this initiative was to make sure that women from deprived communities in the U.S. get access to effective contraception.

Scope of the Report

By Type

• Hormonal Intrauterine Device
• Copper Intrauterine Device

By Application

• Hospitals
• Gynaecology Centers
• Community Healthcare Centers
• Others

1. Research Framework
1. Research Objective
2. Product Overview
3. Market Segmentation
2. . Research Methodology
1. Qualitative Research
1. Primary and Secondary Products
2. Quantitative Research
1. Primary and Secondary Products
3. Breakdown of Primary Research Respondents
1. Secondary Research
2. Primary Research
4. Breakdown of Primary Research Respondents, By Industry Participants
5. Market Breakdown & Data Triangulation
3. Executive Summary
4. U.S. IUD Market – Industry Insights
1. Industry Value Chain Analysis
2. DROC Analysis
1. Growth Drivers
2. Restraints
3. Opportunity
4. Challenges
3. Recent Developments
4. Regulatory Framework
5. Porter Five Forces Analysis
5. US IUD Market Overview

5.1. Market Size & Forecast by Value, 2017-2027

1. By Value (USD Million)
2. By Volume (Thousand Units)

5.2. Market Share & Forecast

1. By Type
1. Hormonal Intrauterine Device
2. Copper Intrauterine Device
2. .   By End-User
1. Hospitals
2. Gynaecology Centres
3. Community Healthcare Centres
6. US IUD Competitive Landscape
1. List of Key Players and Their Offerings
2. Market Share Analysis (2020)
3. Competitive Benchmarking, By Operating Parameters
7. IUD MARKET: Top 4 Company Ranking Analysis, 2020
8. Top 5 Brands Analysis in IUD Market
9. Impact of COVID-19 Across IUD Industry

10. List of IUD Clinical Trials

11. Which IUD is Right for Use

12. How much Does an IUD Cost (And Will Insurance Cover It)?

13. Insurance Coverage and Financing of IUDs

14.  Company Profiles (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

14.1. Bayer AG

14.2. Allergan PLC

14.3. Cooper Companies (CooperSurgical Inc)

15. Key Strategic Recommendations

*Financial details of unlisted companies will be available as per data availability in final deliverable

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable.

List of Figures.

Fig 1: U.S. IUDs Segmentation

Fig 2: U.S. IUDs Market Size, By Value (USD Million)

Fig 3: U.S. IUDs Market Share, By End-User, By Value (in %), 2020

Fig 4: U.S. IUD: Value Chain Analysis Market: Healthcare Industry Value Chain

Fig 5: Process of a Clinical Trial & Approval

Fig 6: Estimated numbers of women (Million) of reproductive age (15-49 years) using various contraceptive methods, 1994 and 2019

Fig 7 - Estimated IUD prevalence of individual contraceptive methods among women of reproductive age (15-49 years), 2019

Fig 8:  U.S. Women Healthcare Density

Fig 9: Porters Five Forces Analysis

Fig 10: U.S. IUDs Market Size, By Value (USD Million), 2017-2027

Fig 11: U.S. IUDs Market Size, By Volume (Thousand Units), 2017-2027

Fig 12: U.S. IUDs Market Share (%), By Type, By Value, 2017-2027

Fig 13: U.S. IUDs Market Share (%), By Type, By Volume, 2017-2027

Fig 14: U.S. IUDs Market Share (%), By End-User, By Value, 2017-2027

Fig 15: U.S. IUDs Market Share (%), By End-User, By Volume, 2017-2027

Fig 16: List of Key Players and Their Offerings

Fig 17: U.S. IUDs: Market/Ranking Share Analysis, 2020

Fig 18: Use of Contraceptive Among Women Aged 18-49 at Risk of Unintended Pregnancy, 2017

Fig 19: Ranking of Leading Players in U.S. IUD Market

Fig 20: Top 5 Brands Analysis in IUD Market

Fig 21: % of Women's Reporting Delays/Cancellation During COVID-19 for Contraceptive and Other SRH Care

Fig 22: Tiered Discounts for Mirena Purchases

Fig 23: Tiered Discounts for Skyla Purchases

Fig 24: Tiered Discounts for Liletta Purchases

Fig 25: Tiered Discounts for ParaGard Purchases

List of Tables.

Table 1: Types of IUDs

Table 2: Types of IUDs, Their Years Effective and Use

Table 3: U.S. Government-Funded Family Planning/Reproductive Health (FP/RH) Interventions

Table 4: U.S. IUDs Market Size, By Type, By Value (USD Million), 2017-2027

Table 5: U.S. IUDs Market Size, By Type, By Volume (Thousand Units), 2017-2027

Table 6: U.S. IUDs Market Size, By End-Users, By Value (USD Million), 2017-2027

Table 7: U.S. IUDs Market Size, By End-Users, By Volume (Thousand Units), 2017-2027

Table 8: Competitive Benchmarking, by Operating Parameters

Table 9: List of IUD Clinical Trials

Table 10: Comparison Chart of IUS’s for Right Selection

Table 11: Comparison Chart of IUS’s for Right Selection

Table 12: IUD Brand Wise Average Cost Analysis, 2020

Table 13: Bayer AG Company Overview

Table 14: Bayer AG. Financial Analysis (USD Million)

Table 15: Abbvie Inc. Company Overview

Table 16: Abbvie Inc. Financial Analysis (USD Million)

Table 17: Cooper Companies (CooperSurgical Inc) Company Overview

Table 18: Cooper Companies (CooperSurgical Inc) Financial Analysis (USD Million)

Table 19: IUD Products Under Clinical Trials in the United States